Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Report from the SENTRY Antimicrobial Surveillance Program, 2016 [PublishAheadOfPrint]

Omadacycline was tested against 21,000 bacterial isolates collected prospectively from medical centers in Europe and the United States during 2016. Omadacycline was active against Staphylococcus aureus (MIC_50/90, 0.12/0.25 mg/L) including MRSA; streptococci (MIC_50/90, 0.06/0.12 mg/L) including Streptococcus pneumoniae, viridans group streptococci, and β-hemolytic streptococci; Enterobacteriaceae including Escherichia coli (MIC_50/90, 0.5/2 mg/L); Haemophilus influenzae (MIC_50/90, 1/1 mg/L); and Moraxella catarrhalis (MIC_50/90, 0.25/0.25 mg/L). Omadacycline merits further study in serious infections where resistant pathogens may be encountered.

http://ift.tt/2DNRrAU